The importance of “disclosure” in relationships between physicians and pharmaceutical companies

Makowska, Marta; Jasiński, Łukasz

dc.contributor.author	Makowska, Marta
dc.contributor.author	Jasiński, Łukasz
dc.date.accessioned	2019-04-03T08:57:04Z
dc.date.available	2019-04-03T08:57:04Z
dc.date.issued	2018
dc.identifier.issn	1899-2226
dc.identifier.uri	http://hdl.handle.net/11089/27306
dc.description.abstract	The article raises issues of transparency in relationships between doctors and drug manufacturers. It indicates how important it is as a way for physicians and the pharmaceutical industry to regain public trust. The manuscript will define the concept of disclosure. It will discuss in detail The Physician Payment Sunshine Act from the U.S., which imposes a legal obligation on pharmaceutical companies to disclose their relationships with doctors and university hospitals. The article will also show the diverse regulation of disclosure in different countries of the European Union. The situation in Poland will be also described. In the summary, there will be a discussion about the importance of disclosure for patients and the advantages and disadvantages of such regulations for physicians and drug manufacturers.	en_GB
dc.description.sponsorship	Publication of English-language versions of the volumes of the "Annales. Ethics in Economic Life" financed through contract no. 501/1/P-DUN/2017 from the funds of the Ministry of Science and Higher Education devoted to the promotion of scholarship.	en_GB
dc.language.iso	en	en_GB
dc.publisher	Wydawnictwo Uniwersytetu Łódzkiego	en_GB
dc.relation.ispartofseries	Annales. Ethics in Economic Life; 5
dc.rights	This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.	en_GB
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0	en_GB
dc.subject	conflict of interest	en_GB
dc.subject	disclosure	en_GB
dc.subject	ethical standard	en_GB
dc.subject	pharmaceutical industry	en_GB
dc.title	The importance of “disclosure” in relationships between physicians and pharmaceutical companies	en_GB
dc.type	Article	en_GB
dc.page.number	81-94
dc.contributor.authorAffiliation	Warsaw University of Life Sciences, Faculty of Social Sciences, Department of Sociology
dc.contributor.authorAffiliation	Maria Curie Skłodowska University of Lublin, Faculty of Economics
dc.identifier.eissn	2353-4869
dc.references	AdvaMed. (n.d.) The Physician Sunshine Act and you. http://advamed.org/res.download/60	en_GB
dc.references	Agrawal, S., Brennan, N., & Budetti, P. (2013). The Sunshine Act—effects on physicians. New England Journal of Medicine, 368(22), 2054–2057.	en_GB
dc.references	American Medical Association. (n.d.). Sunshine Act FAQs. http://www.amaassn.org/ama/pub/advocacy/topics/sunshine-act-and-physician-financialtransparency-reports/sunshine-act-faqs.page?	en_GB
dc.references	Belluz, J. (2014, September 30). Doctors and hospitals got at least $3.5 billion from industry in just five months. Vox. http://www.vox.com/2014/9/30/6868897/you-can-now-search-for-your-doctors-pharma-payments-online-sunshine-act	en_GB
dc.references	Campbell, E. C., Gruen, R. L., Mountford, J., Miller, L. G., Cleary, P. D., & Blumenthal, D., (2007). A National Survey of Physician – Industry Relationships. The New England Journal of Medicine, 356, 1742–1750.	en_GB
dc.references	CBOS [Centre for Public Opinion Research]. (1999). Prestiż zawodów [Prestige of profession]. Warszawa: CBOS.	en_GB
dc.references	CBOS [Centre for Public Opinion Research]. (2013). Prestiż zawodów [Prestige of profession]. Warszawa: CBOS.	en_GB
dc.references	CBOS [Centre for Public Opinion Research]. 2016. Społeczne oceny uczciwości i rzetelności zawodowej [Social evaluation of honesty and professional integrity]. Warszawa: CBOS.	en_GB
dc.references	Centers for Medicare & Medicaid Services. (n.d.) Fact Sheet for Physcians, https://www.cms.gov/Regulations-and-Guidance/Legislation/National-Physician-Payment-Transparency-Program/Downloads/Physician-fact-sheet .pdf	en_GB
dc.references	Centers for Medicare & Medicaid Services. (n.d.) Open Payments Data Summary. https://openpaymentsdata.cms.gov/summary	en_GB
dc.references	Ciadini, R. (2003). Wywieranie wpływu na ludzi. Teoria i praktyka. Gdańsk: Gdańskie Wydawnictwo Psychologiczne.	en_GB
dc.references	The CMS Blog. (2016). CMS Releases Third Year of Open Payments Data. https://blog.cms.gov/2016/06/30/cms-releases-third-year-of-open-payments-data/	en_GB
dc.references	Dhuri, S. (2013). Comparison of the French sunshine act. (Loi Bertrand Law) and the US Sunshine Act. https://pharmapromotional.wordpress.com/2013/09/30/comparison-of-the-french-sunshine-act-loi-bertrand-law-and-the-us-sunshine-act/	en_GB
dc.references	Hajnosz, I., & Wróblewski, H. (2007). To jak pan korumpował lekarza. Gazeta Wyborcza, 182, p. 6.	en_GB
dc.references	Halperin, E. C., Hutchison, P., & Barrier Jr, R. C. (2004). A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers. International Journal of Radiation Oncology • Biology • Physics, 59(5), 1477–1483.	en_GB
dc.references	INFARMA. (2008). Kodeks Dobrych Praktyk Przemysłu Farmaceutycznego [Code of Good Practice of the Pharmaceutical Industry]. http://www.infarma. pl/assets/files/etyka/KodeksDobrych Praktyk_Wyd_2_201014_PL.PDF	en_GB
dc.references	INFARMA. (2015). Kodeks przejrzystości [Transparency Code], http://www.kodeksprzejrzystosci.pl/assets/files/etyka/Kodeks_Przejrzystosci_wydanie_5.pdf	en_GB
dc.references	INFARMA. (2015–2017). Raport przejrzystości. http://www.kodeksprzejrzystosci.pl/raporty/	en_GB
dc.references	INFARMA. (2016). Czym jest Kodeks Przejrzystości. http://www.kodeksprzejrzystosci.pl/kodeks-przejrzysto%C5%9Bci/	en_GB
dc.references	Kruczkowska, M. (2013). Koncerny farmaceutyczne korumpują Chiny. Jeden się pokajał. Gazeta Wyborcza, 172, 8.	en_GB
dc.references	Lieb, K., & Scheurich, A. (2014). Contact between doctors and the pharmaceutical industry, their perceptions, and the effects on prescribing habits. PLoS One, 9(10). doi: 10.1371/journal.pone.0110130	en_GB
dc.references	Lizut, M. (2006). Jak ustawić lekarza. Gazeta Wyborcza, 120, 4.	en_GB
dc.references	Makowska, M. (2010). Etyczne standardy marketingu farmaceutycznego. Warszawa: CeDeWu.	en_GB
dc.references	Makowska, M. (2012). Rola śledztw dziennikarskich w kreowaniu etycznych standardów marketingu farmaceutycznego. Prakseologia, 152, 125–144.	en_GB
dc.references	Makowska, M. (2016). Etyczne wyzwania współpracy studentów medycyny z przemysłem farmaceutycznym. Studium porównawcze sytuacji w USA i Polsce. Warszawa: Wydawnictwo Szkoły Głównej Gospodarstwa Wiejskiego.	en_GB
dc.references	Markowska, M., & Jasiński, Ł. (2017). Znaczenie „przejrzystości” w relacjach lekarzy z firmami farmaceutycznymi. Annales. Ethics in Economic Life, 20(1), 95–109.	en_GB
dc.references	McDermott, Will & Emery. (2014). Snapshot of sunshine rules in EU countries for the pharmaceutical industry. http://documents.jdsupra.com/beee41ce-968c-484e-9eca-73d39615efb1.pdf	en_GB
dc.references	Orlowski, J. P., & Wateska, L. (1992). The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest, 102(1), 270–273.	en_GB
dc.references	Pham-Kanter, G., Alexander, G. C., & Nair, K. (2012). Effect of physician payment disclosure laws on prescribing. Archives of Internal Medicine, 172(10), 819–821.	en_GB
dc.references	PolicyMed. (2016). Open Payments Data Summary. http://www.policymed.com/2016/06/open-pay ments-2015-data-released.html	en_GB
dc.references	Prozilo Life Sciences. (2015). Ready or Not, Full Speed Ahead for the Global Transparency Movement. https://s3-us-west-2.amazonaws.com/porzio/media/1432/porziols-white-paper_august-2015.pdf	en_GB
dc.references	Rabij, M., (2014). Lekarz zdalnie sterowany. Newsweek Polska, 2, 32–35.	en_GB
dc.references	Szymborski, T. (2003). Kasa fundacji zabytków. Rzeczpospolita, 123, A1–A4.	en_GB
dc.references	Wazana, A. (2000). Physicians and the pharmaceutical industry. Is a gift ever just a gift? Journal of American Medical Association, 283(3), 373–380.	en_GB
dc.references	Zverejňovanie na základe zákona č. 362/2011 Z. z. o liekoch a zdravotníckych pomôckach. http://www.nczisk.sk/Medicinska-statistika/Zverejnovanie_na_zaklade-zakona_362-2011_liekoch_zdravotnickych_pomockach/Stranky/default.aspx	en_GB
dc.contributor.authorEmail	marta_makowska@sggw.pl
dc.contributor.authorEmail	lukasz.jasinski@poczta.umcs.lublin.pl
dc.identifier.doi	10.18778/1899-2226.21.5.07
dc.relation.volume	21	en_GB
dc.subject.jel	I18

Pliki tej pozycji

Nazwa:: 5_7_81-94_Makowska M., Jasinski ...
Rozmiar:: 851.5KB
Format:: PDF

Oglądaj/Otwórz

Pozycja umieszczona jest w następujących kolekcjach

Annales. Etyka w życiu gospodarczym 2018, vol. 21 nr 5 [12]

Pokaż uproszczony rekord

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Poza zaznaczonymi wyjątkami, licencja tej pozycji opisana jest jako This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.